Related Experiment Video

Updated: Aug 6, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Platelet glycoprotein IIb/IIIa receptor blockade: lessening the risk of coronary interventions

W R Pitts1, R A Lange

  • 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75235-9047, USA.

Thrombosis and Haemostasis
|March 1, 2000
PubMed

Insights

Platelet glycoprotein IIb/IIIa receptor blockers reduce heart attacks and emergency stenting during percutaneous coronary intervention. These blockers also decrease revascularization needs in diabetic patients undergoing stenting.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pharmacology

Background:

  • Percutaneous coronary intervention (PCI) is a common procedure for treating coronary artery disease.
  • Nonfatal myocardial infarction and unplanned stenting are significant complications of PCI.
  • Diabetic patients undergoing intracoronary stenting face risks of target vessel revascularization.

Purpose of the Study:

  • To evaluate the efficacy of platelet glycoprotein IIb/IIIa receptor blockers in reducing adverse events during PCI.
  • To assess the impact of these blockers on diabetic patients undergoing intracoronary stenting.
  • To summarize the evidence supporting the use of glycoprotein IIb/IIIa receptor inhibitors across various patient groups and PCI procedures.

Main Methods:

  • Review of clinical evidence and studies on platelet glycoprotein IIb/IIIa receptor blockers.
  • Analysis of outcomes in patients undergoing PCI, including myocardial infarction, emergency stenting, and revascularization.
  • Stratification of patient populations (high-risk, low-risk, diabetic) and PCI types (angioplasty, atherectomy, stenting).

Main Results:

  • Administration of platelet glycoprotein IIb/IIIa receptor blockers significantly reduces periprocedural nonfatal myocardial infarction and the need for unplanned emergency stenting in PCI patients.
  • In diabetic patients undergoing intracoronary stenting, these blockers appear to decrease the need for subsequent target vessel revascularization.
  • Evidence supports the use of glycoprotein IIb/IIIa receptor inhibitors in diverse patient categories and for a wide range of percutaneous procedures.

Conclusions:

  • Platelet glycoprotein IIb/IIIa receptor blockers are effective in mitigating key complications associated with percutaneous coronary intervention.
  • These agents offer specific benefits for diabetic patients undergoing intracoronary stenting, reducing the need for repeat procedures.
  • The broad evidence base confirms the utility of glycoprotein IIb/IIIa receptor inhibitors across the spectrum of interventional cardiology practice.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...